Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Moderate-to-severe Plaque Psoriasis

Treatments: Drug: Deucravacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT06258668

IM011-1122

Details and patient eligibility

About

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Enrollment: 505 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants ≥19 years of age
• Diagnosis of moderate-to-severe plaque psoriasis
• Candidate for phototherapy or systemic therapy
• Will begin deucravacitinib according to approved product label

Exclusion criteria

• Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
• Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)

Trial design

505 participants in 1 patient group

Participants diagnosed with moderate-to-severe plaque psoriasis

Treatment:

Drug: Deucravacitinib